Essex Bio-Technology Limited
Essex Bio-Technology Limited Fundamental Analysis
Essex Bio-Technology Limited (1061.HK) shows moderate financial fundamentals with a PE ratio of 6.45, profit margin of 17.54%, and ROE of 13.57%. The company generates $1.8B in annual revenue with weak year-over-year growth of -2.15%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 53.8/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze 1061.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1061.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1061.HK shows balanced valuation metrics.
Growth Score
Moderate1061.HK shows steady but slowing expansion.
Financial Health Score
Excellent1061.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate1061.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 1061.HK Expensive or Cheap?
P/E Ratio
1061.HK trades at 6.45 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1061.HK's PEG of 3.55 indicates potential overvaluation.
Price to Book
The market values Essex Bio-Technology Limited at 0.85 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 5.67 times EBITDA. This is generally considered low.
How Well Does 1061.HK Make Money?
Net Profit Margin
For every $100 in sales, Essex Bio-Technology Limited keeps $17.54 as profit after all expenses.
Operating Margin
Core operations generate 21.31 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.57 in profit for every $100 of shareholder equity.
ROA
Essex Bio-Technology Limited generates $9.11 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Essex Bio-Technology Limited produces operating cash flow of $359.27M, showing steady but balanced cash generation.
Free Cash Flow
Essex Bio-Technology Limited generates strong free cash flow of $253.44M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.45 in free cash annually.
FCF Yield
1061.HK converts 12.35% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
6.45
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
3.55
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.85
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.13
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.14
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.11
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.14
vs 25 benchmark
How 1061.HK Stacks Against Its Sector Peers
| Metric | 1061.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 6.45 | 28.45 | Better (Cheaper) |
| ROE | 13.57% | 763.00% | Weak |
| Net Margin | 17.54% | -45265.00% (disorted) | Strong |
| Debt/Equity | 0.14 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.11 | 2795.60 | Strong Liquidity |
| ROA | 9.11% | -16588.00% (disorted) | Weak |
1061.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Essex Bio-Technology Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
33.05%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
3.54%
Industry Style: Defensive, Growth, Innovation
GrowingFCF CAGR
61.33%
Industry Style: Defensive, Growth, Innovation
High Growth